弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展

doi:10.3760/cma.j.cn441417-20240101-04007

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (4): 559-562.DOI: 10.3760/cma.j.cn441417-20240101-04007

弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展

洪金全¹ 黄晓玲² 黄震宇³ 黄豪博²

¹福建医科大学附属第二医院麻醉科，泉州 362000；²福建医科大学附属协和医院输血科，福州 350001；³福建技术师范学院食品与生物工程学院，福州 350300

收稿日期:2024-09-29 出版日期:2025-02-15 发布日期:2025-02-24
通讯作者: 黄豪博，Email：huanghaobo1981@163.com
基金资助:
福建省科技创新联合资金项目（2019Y9050）

Research progress of abnormal lipid metabolism and its intervention in diffuse large B-cell lymphoma

Hong Jinquan¹, Huang Xiaoling², Huang Zhenyu³, Huang Haobo²

¹Department of Anesthesia, Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, China; ²Department of Blood Transfusion, Fujian Medical University Union Hospital, Fuzhou 350001, China; ³School of Food and Bioengineering, Fujian Polytechnic Normal University, Fuzhou 350300, China

Received:2024-09-29 Online:2025-02-15 Published:2025-02-24
Contact: Huang Haobo, Email: huanghaobo1981@163.com
Supported by:
Joint Funds for Innovation of Science and Technology in Fujian (2019Y9050)

摘要/Abstract

摘要：

脂质代谢异常是恶性肿瘤发生发展中重要的代谢改变。脂质代谢相关基因变化引发的脂质重编程及后续脂质代谢产物异常对于肿瘤细胞的增殖、侵袭和转移具有重要影响。临床与基础研究显示，弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）患者中存在着脂质代谢相关基因及代谢产物的异常表达，且该变化与预后有关；靶向脂质代谢异常的干预可以改变DLBCL细胞生物学行为。因此，本文对DLBCL中存在的脂质代谢异常及其发生机制和靶向脂质代谢的干预进行综述，为挖掘DLBCL的潜在诊治靶点提供有益总结。

关键词:

弥漫大B细胞淋巴瘤, 脂质代谢, 机制, 干预, 进展

Abstract:

Abnormal lipid metabolism is an important metabolic change in the occurrence and development of malignant tumors. Lipid reprogramming caused by changes in lipid metabolism-related genes and subsequent abnormal lipid metabolites have important effects on the proliferation, invasion, and metastasis of tumor cells. Clinical and basic studies have shown that there are abnormal expressions of lipid metabolism-related genes and metabolites in patients with diffuse large B-cell lymphoma (DLBCL), and these changes are related to prognosis. Intervention targeting abnormal lipid metabolism can change the biological behaviors of DLBCL cells. Therefore, this article reviews the abnormal lipid metabolism in DLBCL, its mechanism, and the intervention targeting lipid metabolism, so as to provide a useful summary for exploring the potential diagnosis and treatment targets of DLBCL.

Key words:

Diffuse large B-cell lymphoma, Lipid metabolism, Mechanism, Intervention, Progress

洪金全黄晓玲黄震宇黄豪博.

弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 559-562.

Hong Jinquan, Huang Xiaoling, Huang Zhenyu, Huang Haobo.

Research progress of abnormal lipid metabolism and its intervention in diffuse large B-cell lymphoma [J]. International Medicine and Health Guidance News, 2025, 31(4): 559-562.

参考文献

[1] Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment[J]. Am J Hematol, 2019,94(5):604-616. DOI: 10.1002/ajh.25460.
[2] Ayers EC, Li S, Medeiros LJ, et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure[J]. Cancer, 2020,126(2):293-303. DOI: 10.1002/cncr.32526.
[3] Long J, Zhang CJ, Zhu N, et al. Lipid metabolism and carcinogenesis, cancer development[J]. Am J Cancer Res,2018,8(5):778-791.
[4] 蔡艺威,闫晨名,岳林皓,等. 脂质代谢在乳腺癌进展过程中的重要作用与机制[J]. 国际医药卫生导报,2024,30(15):2470-2473. DOI:10.3760/cma.j.issn.1007-1245.2024. 15.002.
[5] Liebisch G, Fahy E, Aoki J, et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures[J]. J Lipid Res,2020,61(12):1539-1555. DOI: 10.1194/jlr.S120001025.
[6] Fan L, Lin Q, Huang X, et al. Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis[J]. BMC Cancer, 2021,21(1):1255. DOI: 10.1186/s12885-021-08963-6.
[7] Huang X, Wang Y, Huang Z, et al. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study[J]. BMC Cancer, 2024,24(1):62. DOI: 10.1186/s12885-024-11818-5.
[8] Gao R, Liang JH, Wang L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma[J]. Int J Cancer, 2018,143(8):1884-1895. DOI: 10.1002/ijc.31590.
[9] Wang F, Lu L, Chen H, et al. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab[J]. Ann Hematol, 2023,102(2):393-402. DOI: 10.1007/s00277- 023-05092-x.
[10] Li W, Gao M, Xue W, et al. Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis[J]. Chin J Nat Med, 2024,22(6):554-567. DOI: 10.1016/S1875-5364(24)60655-2.
[11] Pera B, Krumsiek J, Assouline SE, et al. Metabolomic profiling reveals cellular reprogramming of B-cell lymphoma by a lysine deacetylase inhibitor through the choline pathway[J]. EBioMedicine, 2018,28:80-89. DOI: 10.1016/j.ebiom.2018.01.014.
[12] Koresawa R, Yamazaki K, Oka D, et al. Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma[J]. Br J Haematol, 2016,174(2):264-274. DOI: 10.1111/bjh. 14054.
[13] Lupino L, Perry T, Margielewska S, et al. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma[J]. Leukemia, 2019,33(12):2884-2897. DOI: 10.1038/s41375-019-0478-9.
[14] Uddin S, Hussain AR, Ahmed M, et al. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma[J]. Mol Cancer Ther, 2010,9(5):1244-55. DOI: 10.1158/1535-7163.MCT-09-1061.
[15] Kapadia B, Nanaji NM, Bhalla K, et al. Fatty acid synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL[J]. Nat Commun, 2018,9(1):829. DOI: 10.1038/s41467-018-03028-y.
[16] Gifford GK, Gifford AJ, Chen Q, et al. Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2020,61(8):1810-1822. DOI: 10.1080/10428194.2020.1742899.
[17] 段素素,雷娜,吴海妹,等. 脂质代谢调控机制及相应药物研究进展[J]. 山东医药,2021,61(20):93-96. DOI:10.3969/j.issn.1002-266X.2021.20.024.
[18] Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer[J]. Cell Metab, 2020,31(1):62-76. DOI: 10.1016/j.cmet.2019.11.010.
[19] Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas[J]. Cancer Cell, 2013,23(6):826-838. DOI: 10.1016/j.ccr.2013.05.002.
[20] Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20[J]. PLoS Med, 2008,5(3):e64. DOI: 10.1371/journal.pmed.0050064.
[21] Song MK, Chung JS, Lee GW, et al. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era[J]. Leuk Res, 2015,39(2):211-215. DOI: 10.1016/j.leukres.2014.12.003.
[22] Smyth L, Blunt DN, Gatov E, et al. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects[J]. Br J Haematol, 2020,191(3):396-404. DOI: 10.1111/bjh. 16635.
[23] Ennishi D, Asai H, Maeda Y, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy[J]. Ann Oncol, 2010,21(6):1217-1221. DOI: 10.1093/annonc/mdp490.
[24] Hohaus S, Tisi MC, Bellesi S, et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy[J]. Cancer Med, 2018,7(1):270-281. DOI: 10.1002/cam4.1166.
[25] Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab[J]. J Clin Oncol, 2014 ,32(29):3242-3248. DOI: 10.1200/JCO.2013.53.4537.
[26] Han J, Tang Y, Zhong M, et al. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line[J]. Mol Med Rep, 2019,20(6):5064-5074. DOI: 10.3892/mmr.2019.10756.

弥漫大B细胞淋巴瘤中脂质代谢异常及其干预的研究进展

Research progress of abnormal lipid metabolism and its intervention in diffuse large B-cell lymphoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李晓童于胜强. 肾小管细胞来源外泌体在肾纤维化中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 712-718.
[2]	张涵孙婷王延飞张肖林车娟. 移植后淋巴组织增生性疾病在儿童扁桃体腺样体肥大中的研究进展 [J]. 国际医药卫生导报, 2025, 31(5): 752-757.
[3]	莫家婵范万峰姜兴岳. 基于磁共振成像的影像组学在垂体腺瘤中的应用现状及进展 [J]. 国际医药卫生导报, 2025, 31(5): 757-760.
[4]	牛亚利蔡春茜武蕊王雪张福庆万春晓. 丁苯酞胶囊对脑梗死后认知功能障碍患者认知功能网络连通性的干预研究 [J]. 国际医药卫生导报, 2025, 31(5): 796-800.
[5]	刘伟锋郭媛唐文洁杨蕊梦樊浩魏新华. “医+X”人才培养模式对医学影像研究生综合能力培养的初探 [J]. 国际医药卫生导报, 2025, 31(4): 530-534.
[6]	郝慧慧冯安华马晓林李敖丁传华. SOAP思维模式下融合案例与问题教学模式在临床药学实习带教中的应用 [J]. 国际医药卫生导报, 2025, 31(4): 539-542.
[7]	王兴兴张肖林王延飞. 间充质干细胞在神经退行性疾病中的研究进展 [J]. 国际医药卫生导报, 2025, 31(4): 562-567.
[8]	曾令果赵洲刘为朋胡宝光. 外科治疗高血压研究进展 [J]. 国际医药卫生导报, 2025, 31(3): 411-415.
[9]	邢文华梁栋刘洁李梦洁张晓敏. 线粒体动力学在糖尿病肾病中的作用及调节机制 [J]. 国际医药卫生导报, 2025, 31(2): 183-187.
[10]	孙虓刘成霞王娜郝佳慧储琳琳于瑞杰. 探讨不良饮食习惯与腐胺及胃炎癌转化的关系 [J]. 国际医药卫生导报, 2025, 31(2): 221-223.
[11]	龙其雄李静纯冯峰孙伟. 基于网络药理学探讨防己-红参抗结直肠癌的作用机制 [J]. 国际医药卫生导报, 2025, 31(2): 252-259.
[12]	李香玉郑慧娟樊艳婷. 儿童流感嗜血杆菌感染特点及疾病进展的影响因素 [J]. 国际医药卫生导报, 2025, 31(2): 265-269.
[13]	姜泽军汤胜宇杨红玲. 炎症标志物在慢性心力衰竭临床预后评估中的作用 [J]. 国际医药卫生导报, 2025, 31(1): 42-46.
[14]	吴京霖卢曼路李明珍刘璐于燕潘磊. 肠道菌群与阻塞性睡眠呼吸暂停综合征合并认知功能障碍的研究进展 [J]. 国际医药卫生导报, 2025, 31(1): 47-50.
[15]	曾宪虎李明李子龙项旭田慧李惠珠马龙杰方笑丽陈力唐冉. 中西医关于溃疡性结肠炎的研究进展 [J]. 国际医药卫生导报, 2024, 30(9): 1415-1418.